• News
  • SAN DIEGO
  • BioTech

Zebra Biologics launches in SD

A new San Diego-based biotechnology firm has been formed to combat a range of diseases from breast cancer to rheumatoid arthritis.

Zebra Biologics Inc., which will have offices in Boston and Shanghai as well as San Diego, plans to commercialize human therapeutic antibodies.

The founding team is being led by Dr. Richard A. Lerner, a contributor to human antibody engineering, including core technology inventions that have resulted in clinically and commercially important human therapeutic antibody biologic drugs such as Humira.

In addition to Lerner, the founders of Zebra include: pharma industry veteran Dr. Phillip Frost, CEO of Opko Health Inc. (NYSE: OPK); Nobel Laureate Dr. Paul Greengard, professor at The Rockefeller University; former GSK Inc. scientist Dr. Gaung Yang, director of The Shanghai Antibody Institute; Chinese industrialist, Feng Gao; and long-time biotech executive Dr. Ronald M. Lindsay, who will serve as chairman of the board and CEO of Zebra.

“We believe this ground-breaking addition to the repertoire of tools used to generate human therapeutics antibodies will have widespread application across all disease areas,” said Lindsay. “In the past 25 years, function blocking or neutralizing antibody therapeutics have revolutionized effective treatments of many cancers and autoimmune disorders such as rheumatoid arthritis, psoriasis and multiple sclerosis."

Orally active small molecule drugs have seen increasing competition in the past two decades from so called “biologics” drugs -- most recently exemplified by antibody-based drugs such as Herceptin and Humira, which treat breast cancer and rheumatoid arthritis, respectively.

Humira recently became the world’s most successful commercial pharmaceutical product with 2013 sales projected to well exceed $10 billion once the numbers are tallied later this quarter.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.